“Ra-SBRT Is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients ”. Journal of Analytical Oncology 8 (November 29, 2019): 71–76. Accessed April 17, 2026. https://www.neoplasiaresearch.com/index.php/jao/article/view/193.